Background: Hypogammaglobulinemia is a complication of B-cell targeting therapies (BCTT), used in vasculitis, rheumatoid arthritis and systemic lupus erythematosus (SLE). Since autoimmune diseases are associated with underlying and induced immune abnormalities, several societies recommend assessing immune function before and during rituximab treatment. In SLE, polyclonal hypergammaglobulinemia is the typical alteration of gammaglobulins, though hypogammaglobulinemia has also been reported.
Methods: This is a cross-sectional study describing immunoglobulin levels measured as part of routine care in patients with lupus nephritis, a group with multiple factors contributing to immunoglobulin abnormalities, including immune dysregulation, immunosuppression and nephrotic syndrome.
Results: Polyclonal hypergammaglobulinemia occurred in 15/83 (18.1%) patients. In contrast, low levels of immunoglobulins were found as follows: selective IgA deficiency 2/83 (2.4%), reduced IgG levels 7/83 (8.4%), reduced IgM 14/83 (16.9%). Only 1 patient required immunoglobulin replacement.
Conclusions: Immunoglobulin abnormalities are frequently found in lupus nephritis, ranging from polyclonal hypergammaglobulinemia to hypogammglobulinemia. Consequently, immunoglobulin levels should be assessed prior to commencing BCTT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702722 | PMC |
| http://dx.doi.org/10.1186/s41927-019-0079-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Nearly all people with Down Syndrome (DS) develop Alzheimer's dementia (AD) by the 7 decade of life. However, whether the alterations in fluid biomarker levels associated with DS follow the same pattern to those observed in other forms of AD is not well understood.
Method: We used mass spectrometry-based proteomics to measure 1116 proteins in cerebrospinal fluid (CSF) across euploid controls (n=130), sporadic late-onset AD (LOAD, n=89), asymptomatic DS (n=117), prodromal DS (n=57), and dementia DS (n=80) cases, and compared the protein changes observed in DS to those in LOAD and to those recently described in autosomal dominant AD (ADAD).
Background: AL002 is a humanized, TREM2-selective, agonistic IgG1 monoclonal antibody. The INVOKE-2 study is the first to test the efficacy and safety of a TREM2 agonistic antibody in participants with Alzheimer's Disease (AD). A Phase 1 study of AL002 demonstrated dose-dependent target engagement and dose-dependent effects on microglial signaling biomarkers; AL002 was well tolerated at all doses tested.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Knight Alzheimer Disease Research Center, St. Louis, MO, USA.
Background: Amyloid-related Imaging Abnormalities (ARIA) are side effects of beta-amyloid plaque-lowering monoclonal antibody drugs (APLmAbs). Understanding of ARIA mechanisms, risks, nature, evolution and optimal approaches to mitigation and management remains incomplete. Sporadic Alzheimer's Disease (AD) trials support ARIA risk factors including higher APLmAb doses/exposures, ApoE4-carrier status, and presence/severity of microhemorrhages (MCH)/superficial siderosis.
View Article and Find Full Text PDFBackground: Since lecanemab, an anti-amyloid monoclonal antibody targeting Aβ protofibrils, only modestly impacts cognition (27% slower cognitive decline over 18 months), tracking the effects on the brain in the early months is a clinical challenge. Serial noncontrast MRI scans are required by the FDA, to assess for the occurrence of amyloid-related imaging abnormalities (ARIA). Arterial spin-labeling MR (ASL-MR) is a 4-minute non-contrast easily-added sequence.
View Article and Find Full Text PDFTargeting hyaluronan synthesis enhances the therapeutic effectiveness of biologics in inflammatory bowel disease.
JCI Insight
January 2025
Department of Gastroenterology and.
Although biologics have been revolutionizing the treatment of inflammatory bowel diseases (IBD) over the past decade, a significant number of patients still fail to benefit from these drugs. Overcoming the nonresponse to biologics is one of the top challenges in IBD treatment. In this study, we revealed that hyaluronan (HA), an extracellular matrix (ECM) component in the gut, is associated with nonresponsiveness to infliximab and vedolizumab therapy in patients with IBD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!